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Patients with human immunodefi-
ciency virus (HIV) infection and latent tuberculosis
are at substantial risk for the development of active
tuberculosis. As a public health measure, prophylac-
tic treatment with isoniazid has been suggested for
HIV-infected persons who have anergy and are in




We conducted a multicenter, random-
ized, double-blind, placebo-controlled trial of six
months of prophylactic isoniazid treatment in HIV-
infected patients with anergy who have risk factors





The study was conducted from November
1991 through June 1996. Over 90 percent of the pa-
tients had two or more risk factors for tuberculosis
infection, and nearly 75 percent of patients were
from greater New York City. After a mean follow-up
of 33 months, tuberculosis was diagnosed in only
6 of 257 patients in the placebo group and 3 of 260
patients in the isoniazid group (risk ratio, 0.48; 95





There were no significant differences between the two
groups with regard to death, the progression of HIV




Even in HIV-infected patients with
anergy and multiple risk factors for latent tuberculo-
sis infection, the rate of development of active tuber-
culosis is low. This finding does not support the use
of isoniazid prophylaxis in high-risk patients with
HIV infection and anergy unless they have been ex-
posed to active tuberculosis. (N Engl J Med 1997;
337:315-20.)
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UBERCULOSIS is the only opportunistic
infection related to infection with the hu-
man immunodeficiency virus (HIV) that
threatens the general public. The spread of
HIV-related tuberculosis has been well documented,





 Persons infected with HIV are es-
timated to be over 100 times as likely as uninfected




 primarily as a result of
the reactivation of a latent tuberculosis infection.
Tuberculosis develops each year in 7 to 10 percent




HIV infection accounted for a substantial propor-
T
 
tion of the excess cases of tuberculosis in the United




The World Health Organization estimated that in
1990 more than 3 million people in the world were










 According to the Centers for Dis-
ease Control and Prevention (CDC), identifying these
people so that prophylaxis with isoniazid can be giv-





ever, the tuberculin skin test, the only available tool





tion, has low sensitivity in HIV-infected persons be-





To prevent tuberculosis from spreading in the Unit-
ed States, the CDC suggested in 1991 that preventive
therapy be considered for HIV-infected persons who
have anergy but belong to “groups in which the prev-













 and the Infectious Dis-





data support the conclusion that certain HIV-infect-





 no study has investigated the benefit of
providing preventive therapy to this population. We
conducted a randomized, placebo-controlled clinical
trial to assess the effectiveness of six months of iso-
niazid prophylaxis in HIV-infected patients with an-
ergy who were at high risk for tuberculosis.
The New England Journal of Medicine 
Downloaded from nejm.org at COLUMBIA UNIV HEALTH SCIENCES LIB on October 13, 2015. For personal use only. No other uses without permission. 













Patients were enrolled at 11 units of the Terry Beirn Commu-
nity Programs for Clinical Research on AIDS. Six units were in
greater New York — four in New York City, one in Newark, New
Jersey, and one in New Haven, Connecticut. The units outside
greater New York were located in New Orleans; Wilmington, Del-
aware; San Francisco; Washington, D.C.; and Detroit. All the pa-
tients had diagnosed HIV infection and characteristics placing





All the patients received 5 tuberculin units of Tween-stabilized
purified protein derivative (PPD), applied by the Mantoux meth-
od; the tests were read 48 to 72 hours after the application. In
addition, the patients underwent delayed-type–hypersensitivity
skin testing with mumps antigen and also with tetanus toxoid in
a 1:10 dilution with allergenic extract. Only patients with anergy,
defined by a reaction to PPD of less than 5 mm induration and
a reaction to both the other antigens of less than 2 mm indura-
tion, were eligible for the study.
The patients were also required to be at least 13 years old,
to have no clinical or radiologic evidence of active tuberculosis,





mol per liter) or less and serum concentrations of aspartate
aminotransferase and alkaline phosphatase that did not exceed
five times the upper limits of normal. Patients were excluded
from the study if, during the preceding year, they had lived in a
household with a person with active tuberculosis or if they were
currently receiving any agent with potential activity against tu-
berculosis. They were also excluded if they had evidence of acute
hepatitis or peripheral neuropathy or a history of a positive PPD
test, intolerance to the study medication, or treatment for one
month or more with agents with potential antituberculous ac-
tivity.
The study protocol was approved by the institutional review
board at each participating site, and written informed consent was
obtained from all patients.
 
Study Design and End Points
 
The study was a randomized, placebo-controlled, double-blind
trial of isoniazid for the prevention of tuberculosis. The patients
received 300 mg of isoniazid or a matching placebo plus, in either




 daily for six months. Patients who did
not complete their treatment within six months were allowed an
additional period of up to six months to complete the regimen.
The study design called for a total of 600 patients to be recruited
over a period of 24 months, and the follow-up period for each
patient was intended to be at least 30 months. The study had an
80 percent power to detect a 60 percent reduction in the risk of




 level, 0.05). It was as-
sumed that the rate of tuberculosis in the placebo group after 36
months would be 15 percent and that the death rate in the pla-
cebo group would be 10 percent per year. A stratified random-
ization with permuted blocks was used with the study unit as the
stratification factor.
The primary end point was active tuberculosis, pulmonary, ex-




 from any source was required. Cultures and sus-
ceptibility tests were performed at local laboratories. Secondary
end points were probable tuberculosis, clinical progression of
HIV disease, and death. Clinical disease progression was defined
as the first occurrence of an acquired immunodeficiency syn-
drome (AIDS)–defining condition according to a description




 or as a recurrence of





candidiasis, herpes simplex infection, disseminated herpes zoster,
and septicemia due to nontyphoidal salmonella. The diagnosis of
probable tuberculosis required clinical evidence from a physical
examination and diagnostic tests, plus either a response to antitu-
berculous therapy or evidence at autopsy of granulomas with or-
ganisms positive for acid-fast bacilli. Cases of tuberculosis that
were not confirmed by culture were reviewed by the Clinical
Events Committee, which was unaware of the treatment assign-
ments. Sputum smears positive for acid-fast bacilli were in them-
selves not sufficient for a diagnosis of confirmed or probable tu-





The initial follow-up visits were scheduled for months 1, 2, 4,
and 6. At months 1, 2, and 6, serum aspartate aminotransferase,
total bilirubin, and alkaline phosphatase were measured. The pa-
tients were next seen at month 12 and every 4 to 6 months there-
after. At each follow-up visit there was a clinical assessment to
detect tuberculosis, hepatitis, peripheral neuropathy, and new
HIV-related diseases. Patients thought to have active tuberculosis
were studied by chest radiography, sputum evaluation, and other
tests as appropriate to the presumed site of infection. Clinicians





During the study, the investigators were kept unaware of the
interim results. Data on toxicity and efficacy were reviewed peri-
odically by an independent Data and Safety Monitoring Board.
The treatment groups were compared with use of the chi-
square test, Fisher’s exact test, Student’s t-test, and the Wilcoxon
rank-sum test. Time-to-event analyses were performed with pro-
portional-hazards regression. Because of the low number of events,
an unstratified, unadjusted analysis was done to evaluate tubercu-
losis-related end points. Both unadjusted and adjusted analyses,
all stratified according to unit, were performed to assess mortality
and the progression of HIV disease; these analyses were adjusted
for the base-line variables shown in Table 1. Subgroup analyses







From November 29, 1991, through January 7,
1994, 517 patients were enrolled in the study; 260
were randomly assigned to isoniazid, and 257 to pla-
cebo. All the patients were followed through June
30, 1996.
The base-line characteristics of the study groups
are shown in Table 1. The two groups were similar.
The mean age was 38 years (range, 21 to 64). The
majority of the patients were black (47 percent) or
Latino (33 percent), 32 percent were women, and
58 percent reported having used injection drugs.
Overall, the median CD4 count was 240 cells per
cubic millimeter (interquartile range, 100 to 417),
and 23 percent of the patients had AIDS.
The distribution of risk factors for tuberculosis in-
fection is shown in Table 2. The two study groups
were similar, except that the placebo group included
higher proportions of people who had been unem-




0.06) or who had
lived with a person with active tuberculosis more





percent of the patients had two or more risk factors
for tuberculosis, and 74 percent lived in the New
York City area.
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In both groups, 63 percent of the patients com-
pleted six months of treatment. Adverse events led
to the permanent discontinuation of the study drug
in 9 percent of the patients in each group. Among
those who discontinued treatment in each group,
approximately half did so during the first two months.
At the end of the study, 6.2 percent of the isoniazid
group (16 patients) and 7.0 percent of the placebo
group (18 patients) were lost to follow-up with
respect to whether they had tuberculosis. The aver-
age duration of follow-up was 34 months in the
isoniazid group and 33 months in the placebo
group.
 
Tuberculosis, Survival, and Progression
of HIV Disease
 
Table 3 shows the rates of tuberculosis, death, and
progression of HIV disease or death (as a combined
variable), with the associated relative risks. Con-
firmed tuberculosis developed in 3 of the 260 pa-
tients in the isoniazid group and 6 of the 257
patients in the placebo group (rates per 100 patient-
years of follow-up, 0.4 and 0.9, respectively; relative





0.30). Susceptibility testing was performed
on isolates from eight of these nine patients, includ-
ing all three in the isoniazid group; the eight isolates
were all found to be susceptible to isoniazid. All
three patients in the isoniazid group had pulmonary
tuberculosis. Four of the patients in the placebo
group had pulmonary tuberculosis, one had extra-
pulmonary tuberculosis, and one had both. There
was one patient with probable pulmonary tubercu-
losis in the isoniazid group, as compared with none
in the placebo group. All the cases of tuberculosis
occurred six months or more after randomization
and after the study drug had been discontinued. Of
the three patients in the isoniazid group who had
tuberculosis, two completed all six months of thera-
py and one completed only four months.
One hundred twenty-nine of the 260 patients in
the isoniazid group died, as compared with 126 of





0.76). The reported causes of death did
not differ between the groups. In one of the six pa-
tients in the placebo group who had tuberculosis,
the tuberculosis was discovered at autopsy but was
not considered to have been the primary cause of
death. No other patient in either group died from
tuberculosis-related causes. One hundred fifty-five
of the 260 patients in the isoniazid group died or
had progression of HIV disease, as compared with
154 of the 257 patients in the placebo group (rela-





Various subgroups were studied with regard to
the combined end point of death or the progression
of HIV disease, and no differences were found
between the study groups. In both groups, the pa-




 cells per cubic mil-
limeter reached the combined end point at substan-
tially higher rates than did the patients with higher
counts. After adjustment for base-line covariates, the
relative risks of both death and the combined end
point of death or progression of HIV disease re-
mained nonsignificant.
 
*Data are based on 240 patients in the isoniazid group and 242 patients
in the placebo group.
†Data are based on 250 patients in the isoniazid group and 246 patients
in the placebo group.





































































Female sex (%) 33.8 30.0 0.35
Mean age (yr) 37.4 38.2 0.24











History of injection-drug use (%)* 57.1 58.7 0.78
Male homosexuality or bisexuality (%)† 28.8 29.3 0.92









) 233.0 247.0 0.48
Use of antiretroviral drugs (%) 72.7 73.2 0.92
*This risk factor refers to birth in a country with a high prevalence of
tuberculosis.
†High-risk areas included the inner city, areas with a high prevalence of
















































































Birth outside U.S.* 20.8 260 18.8 256 0.58






95.4 260 95.7 256 1.00















1 yr 13.6 257 16.3 246 0.45
Household contact before 
the past yr with some-
one with active tuber-
culosis
5.5 217 10.2 215 0.08
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Adverse Events
Twenty-nine patients in the isoniazid group (11.2
percent) and 30 patients in the placebo group (11.7
percent) had reportable adverse events (Table 4).
During the first six months, no patients in the iso-
niazid group and two patients in the placebo group
had reportable events related to peripheral neuropa-
thy. Three patients in the isoniazid group and no pa-
tients in the placebo group had grade III neurop-
athy that did not meet the criteria for an adverse
event. In each group there was one case of grade IV
hepatitis (requiring substantial medical intervention
or therapy and possible hospitalization); in addition,
in the isoniazid group there were 23 cases of sus-
pected hepatitis of lesser severity that did not result
in study-drug discontinuation, as compared with 19
cases in the placebo group. On the basis of labora-
tory data collected in the first six months, 11 pa-
tients in the isoniazid group and 6 patients in the
placebo group had grade III or higher serum aspar-
tate aminotransferase values (more than five times
the upper limit of normal) (P0.32). We found no
differences between groups in the occurrence of ad-
verse events according to age, race, or sex.
DISCUSSION
Isoniazid has been used successfully to prevent re-
activation tuberculosis for the past 40 years.20 More
recently, several investigators have shown the ability
of isoniazid to reduce the incidence of tuberculosis
markedly among HIV-infected persons with positive
PPD tests. In an observational study of HIV-infect-
ed drug users in New York City, persons with posi-
tive PPD tests who did not receive isoniazid ac-
quired tuberculosis at a rate of 9.7 cases per 100
person-years, whereas no tuberculosis developed in
coinfected patients who received isoniazid.16 In a
randomized study of PPD-positive, HIV-infected
patients in Haiti, isoniazid reduced the incidence of
tuberculosis from 10.0 to 1.7 cases per 100 person-
years.6 Similar reductions have been reported in oth-
er studies.7,17 
The ability to diagnose latent tuberculosis in
HIV-infected persons has been hindered by their
reduced response to delayed-type–hypersensitivity
skin tests.13,21 Attempts to increase the sensitivity of
the tuberculin skin test in this population through
the use of a two-stage or “booster” test have not
been successful.22 Therefore, many persons with dual
infection cannot be identified by the clinical tests
currently available. To prevent reactivation tubercu-
losis in such persons, the CDC suggested in 1991
that isoniazid prophylaxis “be considered” for pa-
tients with anergy who are in groups at high risk for
tuberculosis.13 
Our study showed that among such patients, six
TABLE 3. RATES OF EVENTS AND ASSOCIATED RELATIVE RISKS, ACCORDING TO 
TREATMENT GROUP.














Tuberculosis 3 0.4 6 0.9 0.48 (0.12–1.91) 0.30
Death 129 17.7 126 17.8 0.96 (0.75–1.23) 0.76
Progression of HIV 
disease or death
155 26.8 154 27.0 0.97 (0.77–1.21) 0.78
*P values were determined by Fisher’s exact test.
†Adverse events were considered reportable if they were classified as
grade IV (potentially life-threatening) or above on a scale of I to V (with
grade V denoting death) and not considered to be due to the progression
of HIV disease, or if they led to the permanent discontinuation of the
study drug irrespective of the severity of the event. They were recorded
while the patient was taking the study medication and for eight weeks after
its discontinuation.









Any reportable event† 11.2 11.7 0.89
Any event of grade IV or above 5.0 5.8 0.70
Any event probably related to study drug 2.7 0.8 0.18
Permanent discontinuation of study drug 9.2 9.3 1.00
Abnormal liver-function results 1.9 1.6 1.00
Hepatitis 0.4 0.4 1.00
Peripheral neuropathy 0.0 0.8 0.25
Tingling or “pins and needles” 0.4 0.4 1.00
Neutropenia 1.2 0.8 1.00
Anemia 0.4 1.2 0.37
Nausea or vomiting 0.8 1.2 0.68
Diarrhea 0.4 0.4 1.00
Death 1.2 1.9 0.50
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months’ treatment with isoniazid, although safe, was
not effective in preventing tuberculosis or improving
survival. We went to great lengths to identify pa-
tients at substantial risk for tuberculosis. Over 90
percent had two or more risk factors for the disease,
and almost three fourths were from the New York
City area, where HIV-infected persons are known to
have tuberculosis at high rates.23,24 Nevertheless, the
incidence of tuberculosis in the placebo group was
only 0.9 per 100 person-years. This finding is partic-
ularly important, since it may reflect a lower-than-
expected rate of latent tuberculosis infection or an
environment in which the risk of acquiring new tu-
berculosis infections has decreased because of effec-
tive public health measures of control.
Recently, Whalen et al. reported the preliminary
results of a trial of isoniazid prophylaxis among
HIV-infected persons with anergy in Uganda.25 Their
study was also unable to show a benefit of isoniazid
in patients with anergy, because tuberculosis devel-
oped in the patients receiving placebo at a rate of
3.06 per 100 person-years, as compared with 2.53
per 100 person-years for the patients receiving iso-
niazid (P0.68).
Table 5 shows the wide range (2.6 to 12.4 per
100 person-years) in the rate at which tuberculosis
develops among untreated, HIV-infected patients
with anergy according to other studies in this coun-
try and elsewhere. Even though recent studies have
questioned the value and reliability of testing for an-
ergy,26,27 it is clear from several studies that patients
with anergy constitute a distinct group whose risk
for tuberculosis is intermediate between that of tu-
berculin-positive patients and that of patients who
are tuberculin-negative but do not have anergy.7,17
Any potential benefit of preventive therapy would be
even smaller in a population not selected for anergy.
The studies shown in Table 5 differ with regard
to the criteria used to define tuberculosis: some
used clinical definitions, but ours and some others re-
quired cultures positive for M. tuberculosis. Moreno et
al. reported that if only culture-confirmed cases were
considered, the tuberculosis rate would be 8.1, rather
than 12.4, per 100 person-years.17 Pape et al. report-
ed that of 15 cases of tuberculosis they found, only
6 were culture-confirmed.6 Guelar et al. reported that
of the cases in their study, only 65 percent were cul-
ture-confirmed.7 The rates of tuberculosis reported in
these studies may therefore be overestimated.
It is not known whether the cases of tuberculosis
in our study or the others represent reactivations or
new infections. All the studies except one were con-
ducted in the period from the late 1980s to the early
1990s, when tuberculosis-control efforts were inef-
fective both in the United States and elsewhere.9,10,12
Studies conducted during that period showed that
over one third of tuberculosis cases in San Francisco
were apparently due to recent infections,3 as were up
to 40 percent of cases in New York City.23 Our study
was largely conducted after tuberculosis-control ef-
forts nationwide had improved, and particularly those
in New York City, so that rates of tuberculosis de-
creased.24 Thus, it is likely that the low rate of tuber-
culosis we observed largely resulted from reactiva-
tion, whereas the other studies may have included a
substantial number of cases due to recent infection.
In considering the possible benefits of isoniazid
prophylaxis for any group, the toxic effects of the
drug must be considered. Although 12 months of
isoniazid therapy is recommended for HIV-infected
persons with a known risk of tuberculosis,11 we elect-
ed to use the 6-month regimen recommended for
HIV-negative patients in order to reduce the risk of
toxic effects for study patients who were not infected
with tuberculosis. The rate of adverse events did not
differ statistically between the isoniazid group and
the placebo group. Thus, isoniazid appeared to be
safe in these patients even though many of them had
histories of drug or alcohol abuse. Isoniazid has
been associated with hepatotoxicity and death, how-















Study site Spain Spain Haiti Italy U.S. U.S.
Period of study 1985–1991 1989–1992 1986–1992 1990–1993 1988–1990 1991–1996
No. of patients 112 235 35 1649 68 257
No. of person-years 160 308 88 2067 76 673
Injection-drug use — % of patients 80 60 — 72 100 59
CD4 count  — mean or median 135 377 — 200 330 247
Tuberculosis — cases/100 person-













Deaths — no./100 person-yr 33.8 — — 27.0 — 17.7
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ever.28 Therefore, its known toxic effects must be
taken into account when one considers using it in
persons without confirmed latent tuberculosis.
We evaluated the effectiveness of isoniazid pro-
phylaxis for HIV-infected persons with anergy who
were at risk for tuberculosis. Because of the low in-
cidence of tuberculosis in our study, we found no
significant benefit associated with isoniazid use. Our
study population was highly representative of pa-
tients perceived to be at risk for tuberculosis in the
United States, and without a more accurate method
of detecting latent tuberculosis, we believe it would
be impossible to identify people likely to benefit
from prophylaxis. The results of our study, therefore,
do not support the use of preventive therapy with
isoniazid among HIV-infected persons with anergy
in the United States, except in specific high-risk sit-
uations, such as that of people who have recently
come in close contact with someone who has active
tuberculosis.
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